MaxCyte, Inc. Grant of Options (8081R)
March 05 2019 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 8081R
MaxCyte, Inc.
05 March 2019
MaxCyte, Inc.
("MaxCyte" or the "Company")
Grant of Options
Maryland, USA - 05 March 2019: MaxCyte (LSE: MXCT, MXCS), the
global cell-based medicines and life sciences company, announces
that on 04 March 2019, a total of 729,200 options of common stock
in the Company ("Common Stock") were granted to PDMRs who are
directors or officers of the Company ("Option Grants"). Details of
the Option Grants are given below:
Option Grants to PDMRs
Doerfler, Doug 390,200
--------
Holtz, Ron 177,600
--------
Thompson, J. Stark 26,900
--------
Mandell, Art 26,900
--------
Erck, Stan 26,900
--------
Brooke, Will 26,900
--------
Johnston, John 26,900
--------
Douglas, Richard 26,900
--------
Total 729,200
--------
Options Grants to PDMRs vest ratably on a monthly basis over 48
months, have an exercise period of 10 years from date of grant, at
which time they will expire, and have an exercise price equal to
the closing price of MaxCyte's stock on 04 March 2019, of 177.50
pence.
The information set out below is provided in accordance with the
requirements of Regulation 19(3) of the EU Market Abuse Regulation
No 596/2014:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Names Doerfler, Doug
Holtz, Ron
Thompson, J. Stark
Mandell, Art
Erck, Stan
Brooke, Will
Johnston, John
Douglas, Richard
--------------------------- ---------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Doerfler, Doug - CEO and Director
Holtz, Ron - CFO and Director
Thompson, J. Stark - Non-executive Chairman
Mandell, Art - Non-executive Director
Erck, Stan - Non-executive Director
Brooke, Will - Non-executive Director
Johnston, John - Non-executive Director
Douglas, Richard - Non-executive Director
--------------------------- ---------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- ---------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name MaxCyte, Inc.
--------------------------- ---------------------------------------------
b) LEI 54930053YHXULRFCU991
--------------------------- ---------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--------------------------------------------------------------------------
a) Description of the Grant of Options over Shares of Common
financial instrument, Stock
type of instrument
--------------------------- ---------------------------------------------
b) Identification code US57777K1060
--------------------------- ---------------------------------------------
c) Nature of the transactions
Grant of Options to PDMRs
--------------------------- ---------------------------------------------
d) Price(s) and volume(s) Doerfler, Doug - 390,200 at an exercise
price of 177.50 pence
Holtz, Ron - 177,600 at an exercise price
of 177.50 pence
Thompson, J. Stark - 26,900 at an exercise
price of 177.50 pence
Mandell, Art - 26,900 at an exercise price
of 177.50 pence
Erck, Stan - 26,900 at an exercise price
of 177.50 pence
Brooke, Will - 26,900 at an exercise price
of 177.50 pence
Johnston, John - 26,900 at an exercise
price of 177.50 pence
Douglas, Richard - 26,900 at an exercise
price of 177.50 pence
--------------------------- ---------------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
--------------------------- ---------------------------------------------
e) Date of the transactions 04 March 2019
--------------------------- ---------------------------------------------
f) Place of the transaction Outside a trading venue
--------------------------- ---------------------------------------------
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA therapies for its own
pipeline. CARMA is MaxCyte's mRNA-based proprietary platform for
autologous cell therapy. In addition, through its core business,
the Company leverages its Flow Electroporation(R) Technology to
enable its partners across the biopharmaceutical industry to
advance the development of innovative medicines, particularly in
cell therapy, including gene editing and immuno-oncology. The
Company has placed its cutting-edge flow electroporation
instruments worldwide, with all of the top ten global
biopharmaceutical companies, has more than 55 partnered programme
licences in cell therapy including more than 25 licensed for
clinical use. With its robust delivery technology, MaxCyte helps
its partners to unlock the full potential of their products. For
more information, visit www.maxcyte.com
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer
Nominated Adviser and Broker
Panmure Gordon (UK) Limited
Emma Earl (Corporate Finance)
Freddy Crossley
James Stearns (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)20 3709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEANDLEDPNEFF
(END) Dow Jones Newswires
March 05, 2019 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024
